Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Nordson Corporation (Nasdaq: NDSN) announced a strategic realignment of its business segments effective August 1, 2022. The new structure includes three segments: Industrial Precision Solutions (IPS), Medical and Fluid Solutions (MFS), and Advanced Technology Solutions (ATS). This change aims to enhance visibility in growing medical and electronics platforms. In fiscal 2021, IPS generated approximately $1.2 billion, MFS $0.6 billion, and ATS $0.5 billion in revenues. The company remains focused on top-tier growth with a commitment to innovative solutions across diverse end markets.
Danaher Corporation (NYSE: DHR) has appointed Feroz Dewan to its Board of Directors, increasing the board size from thirteen to fourteen members. Dewan, currently CEO of Arena Holdings Management, brings extensive experience from Tiger Global Management and Silver Lake Partners. His appointment aims to enhance Danaher's financial acumen and technology expertise, as noted by Chairman Steven M. Rales. Danaher is committed to innovation in healthcare, environmental and applied markets, supported by a team of approximately 80,000 associates.
Danaher Corporation (NYSE: DHR) will host a webcast for its second quarter 2022 earnings conference call on July 21, 2022, starting at 8:00 a.m. ET. The call, anticipating a duration of approximately one hour, will be accessible via the Investors section of Danaher's website. A replay will be available post-call until August 4, 2022. The earnings press release, along with slide presentations, will be posted online from 6:00 a.m. ET on the day of the call.
SCIEX, a member of Danaher Corporation (NYSE:DHR), has launched SCIEX OS software v3.0 at ASMS 2022, aiming to enhance laboratory efficiency and integration. The software supports their mass spectrometry portfolio and introduces features such as Zeno SWATH DIA and stMRM, promoting superior data quality and workflow enhancements. The new Central Administration Console simplifies project management and security, while accessibility has been boosted with support for nine languages, enabling a global reach.
SciEX, part of Danaher Corporation (NYSE:DHR), has launched Zeno SWATH DIA, enhancing biomarker discovery through improved sensitivity and speed. The new system can quantify up to 2x the proteins in cell and plasma samples, significantly boosting clinical test development. Researchers can achieve large population-scale proteomic studies in weeks with 5-minute run-times, optimizing costs and sample usage. This advancement is expected to drive new therapies and precision medicine, reflecting a significant step forward in translational OMICS research.
Danaher Corporation (NYSE: DHR) has joined the Bespoke Gene Therapy Consortium (BGTC) to enhance the development of customized gene therapies for rare diseases. Launched in October 2021, the BGTC aims to create efficient, cost-effective resources for the research community. Collaborating with key health organizations, Danaher will contribute its significant expertise in genomic medicines through its subsidiaries, including Pall Corporation and Cytiva. This initiative seeks to address challenges in the current drug development model, facilitating faster and more affordable solutions for patients in need.
Danaher Corporation (NYSE: DHR) announced a quarterly cash dividend of $0.25 per share for its common stock, payable on July 29, 2022, to shareholders of record by June 24, 2022. Additionally, a dividend of $12.50 per share for its 5.00% Series B Mandatory Convertible Preferred Stock will be paid on July 15, 2022, to record holders by June 30, 2022. This reflects Danaher's commitment to returning value to its shareholders while maintaining its operational strengths across various markets.
At TIDES 2022, SCIEX announced the launch of the RNA 9000 Purity & Integrity kit designed for high-resolution analysis of mRNA therapeutics. This kit enhances the integrity and quality control of RNA, essential for RNA-based therapeutics and vaccines amidst a growing demand. The kit is compatible with the BioPhase 8800 and PA 800 Plus systems, streamlining analysis and reducing time to market. It allows scientists to accurately gauge therapeutic sizes and detect low-level impurities, ultimately supporting the development of impactful RNA medicines.
Danaher Corporation (NYSE: DHR) announced that CEO Rainer M. Blair will present at the Bank of America Securities Health Care Conference in Las Vegas, Nevada, on May 11, 2022, at 10:00 a.m. PT. The event will be webcast live on Danaher’s official website. Danaher is a global innovator in science and technology, focusing on solving complex challenges in health care, environmental, and applied markets. With approximately 80,000 associates, Danaher operates through over 20 companies united by its business system and shared purpose of 'Helping Realize Life's Potential.'
Danaher Corporation (NYSE: DHR) announced its Q1 2022 results, reporting net earnings of $1.7 billion ($2.31 per diluted share), marking a 1.0% year-over-year increase. Non-GAAP adjusted diluted net earnings rose 9.5% to $2.76 per share. Revenues hit $7.7 billion, reflecting a 12.0% increase, with 12.0% non-GAAP core revenue growth. Operating cash flow stood at $2.0 billion. For Q2 2022, non-GAAP base business core revenue growth is projected in the mid-single digits, impacted by COVID-19 shutdowns in China. The full year 2022 growth is expected in the high-single digits.